Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Huntington's disease (HD)

Histone deacetylase 3 (HDAC3); huntingtin (HTT)

Cell culture studies suggest HDAC3 inhibitors could help treat HD. In rat and mouse neurons expressing mutant HTT, Hdac3 deficiency increased survival compared with normal Hdac3 expression. Ongoing work includes generating Hdac3-deficient mouse models of HD and testing RG2833, an HDAC3 inhibitor from Repligen Corp., in cell culture models of HD.
RG2833 is in Phase I testing to treat ataxia.

SciBX 6(31); doi:10.1038/scibx.2013.829
Published online Aug. 15, 2013

Unpatented; unlicensed

Bardai F.H. et al. J. Neurosci.; published online July 17, 2013;
doi:10.1523/JNEUROSCI.5831-12.2013
Contact: Santosh R. D'Mello, University of Texas at Dallas, Richardson, Texas
e-mail:

dmello@utdallas.edu